CBT
FBRX icon

Capital Bank & Trust’s Forte Biosciences FBRX Stock Holding History

Capital Bank & Trust’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-133
Closed -$334K – 807
2019
Q2 		$334K Hold
133
– – ﹤0.01% 255
2019
Q1 		$544K Buy
133
+36
+37% +$139K 0.01% 216
2018
Q4 		$297K Sell
97
-36
-27% -$155K ﹤0.01% 251
2018
Q3 		$780K Hold
133
– – 0.01% 201
2018
Q2 		$467K Hold
133
– – 0.01% 226
2018
Q1 		$593K Hold
133
– – 0.01% 202
2017
Q4 		$513K Buy
+133
New +$531K 0.01% 215

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital Bank & Trust's FBRX Position: Q3 2019 in Review

Capital Bank & Trust sold out of Forte Biosciences (FBRX) in Q3 2019, closing a stake of 133 shares — an estimated $334K sold.

Capital Bank & Trust first reported a position in FBRX in Q4 2017 and held it in 7 quarters. The position peaked at $780K in Q3 2018. 58 funds tracked by Wall St. Rank hold FBRX as of Q3 2019.

  • Capital Bank & Trust reported no remaining Forte Biosciences position as of Q3 2019 after selling out during the quarter.
  • Capital Bank & Trust sold 133 Forte Biosciences shares in Q3 2019, an estimated $334K.
  • Capital Bank & Trust first reported a position in Forte Biosciences in Q4 2017 and held it in 7 quarters.
  • Capital Bank & Trust's Forte Biosciences position peaked at $780K in Q3 2018.
  • 58 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2019.

Based on Capital Bank & Trust's 13F filing for Q3 2019, filed 14 Nov 2019.